Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial...
Phase 2 “KidCOVE” study of mRNA-1273 in young children:The Phase 2 study of mRNA-1273 in pediatric population ages 6 months to 11 years will start in the near-term. Phase 1/2 study of mRNA-1273 in Japan: The Phase 1/2 study of Moderna’s vacci...